Iowis Zhu

Iowis Zhu

Auto-generated profile, based on publicly available information

Iowis Zhu

Department of Radiation Oncology, University of California San Francisco , San Francisco, California

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 April 2022 in Cell
Verified
Journal Article
Closed access
IZIowis Zhu
Iowis Zhu
RLRaymond Liu
Raymond Liu
JGJulie M. Garcia
Julie M. Garcia
AHAxel Hyrenius-Wittsten
Axel Hyrenius-Wittsten
DPDan I. Piraner
Dan I. Piraner
KRKole T. Roybal
Kole T. Roybal

24 March 2014 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
JLJinghua Lu
Jinghua Lu
YYYadong Yu
Yadong Yu
IZIowis Zhu
Iowis Zhu
YCYifan Cheng
Yifan Cheng
PSPeter D. Sun
Peter D. Sun
Significance: Serum amyloid A (SAA) is a major serum acute-phase protein and a cause of secondary amyloidosis, which impacts ∼1% of patients with chronic inflammation such as rheumatoid arthritis and neoplastic diseases. The lack of structural information has hampered our understanding of SAA-mediated amyloidosis and the development of effective therapies. Here we report a crystal structure of human SAA1.1 as a prototypic member of the family. SAA1.1 exists as a hexamer with subunits displaying a unique four-helix bundle fold. We further defined binding sites for heparin and high-density lipoprotein, identified major amyloidogenic epitopes, and visualized SAA-mediated protofibril formation using electron microscopy. These studies provide mechanistic insights into amyloidogenic conformational transition of SAA.

7 February 2024 in Nature
Verified
Journal Article
Closed access
PDF file
JGJulie Garcia
Julie Garcia
JDJay Daniels
Jay Daniels
YLYujin Lee
Yujin Lee
IZIowis Zhu
Iowis Zhu
KCKathleen Cheng
Kathleen Cheng
JCJaehyuk Choi
Jaehyuk Choi

14 November 2024 in Nature
Verified
Journal Article
Open access
PDF file
DPDan I. Piraner
Dan I. Piraner
MAMohamad H. Abedi
Mohamad H. Abedi
MGMaria J. Duran Gonzalez
Maria J. Duran Gonzalez
ACAdam Chazin-Gray
Adam Chazin-Gray
ALAnnie Lin
Annie Lin
KRKole T. Roybal
Kole T. Roybal
Despite recent advances in mammalian synthetic biology, there remains a lack of modular synthetic receptors that can robustly respond to soluble ligands and, in turn, activate bespoke cellular functions. Such receptors would have extensive clinical potential to regulate the activity of engineered therapeutic cells, but so far only receptors against cell-surface targets have approached clinical translation1. To address this gap, here we adapt a receptor architecture called the synthetic intramembrane proteolysis receptor (SNIPR) for activation by soluble ligands. Our SNIPR platform can be activated by both natural and synthetic soluble factors, with notably low baseline activity and high fold activation, through an endocytic, pH-dependent cleavage mechanism. We demonstrate the therapeutic capabilities of the receptor platform by localizing the activity of chimeric antigen receptor (CAR) T cells to solid tumours in which soluble disease-associated factors are expressed, bypassing the major hurdle of on-target off-tumour toxicity in bystander organs. We further apply the SNIPR platform to engineer fully synthetic signalling networks between cells orthogonal to natural signalling pathways, expanding the scope of synthetic biology. Our design framework enables cellular communication and environmental interactions, extending the capabilities of synthetic cellular networking in clinical and research contexts.

9 July 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
XLXiaoyang Liu
Xiaoyang Liu
SPSenthilkumar Palaniyandi
Senthilkumar Palaniyandi
IZIowis Zhu
Iowis Zhu
JTJin Tang
Jin Tang
WLWeizhong Li
Weizhong Li
XZXiaoping Zhu
Xiaoping Zhu
Human cytomegalovirus (HCMV) can persistently infect humans, but how HCMV avoids humoral immunity is not clear. The neonatal Fc receptor (FcRn) controls IgG transport from the mother to the fetus and prolongs IgG half-life. Here we show that US11 inhibits the assembly of FcRn with β2m and retains FcRn in the endoplasmic reticulum (ER), consequently blocking FcRn trafficking to the endosome. Furthermore, US11 recruits the ubiquitin enzymes Derlin-1, TMEM129 and UbE2J2 to engage FcRn, consequently initiating the dislocation of FcRn from the ER to the cytosol and facilitating its degradation. Importantly, US11 inhibits IgG-FcRn binding, resulting in a reduction of IgG transcytosis across intestinal or placental epithelial cells and IgG degradation in endothelial cells. Hence, these results identify the mechanism by which HCMV infection exploits an ER-associated degradation pathway through US11 to disable FcRn functions. These results have implications for vaccine development and immune surveillance.

10 July 2023 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
IZIowis Zhu
Iowis Zhu
DPDan I. Piraner
Dan I. Piraner
KRKole T. Roybal
Kole T. Roybal
The immune system includes an array of specialized cells that keep us healthy by responding to pathogenic cues. Investigations into the mechanisms behind immune cell behavior have led to the development of powerful immunotherapies, including chimeric-antigen receptor (CAR) T cells. Although CAR T cells have demonstrated efficacy in treating blood cancers, issues regarding their safety and potency have hindered the use of immunotherapies in a wider spectrum of diseases. Efforts to integrate developments in synthetic biology into immunotherapy have led to several advancements with the potential to expand the range of treatable diseases, fine-tune the desired immune response, and improve therapeutic cell potency. Here, we examine current synthetic biology advances that aim to improve on existing technologies and discuss the promise of the next generation of engineered immune cell therapies.